Regions Hospital started a multidisciplinary antibiotic stewardship program (ASP) in 1998. The program effectively shut down from 2002–2004 as key personnel departed and was then restarted but without the dedicated pharmacist and infectious diseases physician. Purchasing data (in dollars or dollars/patient/day) unadjusted for inflation served as a surrogate marker of antibiotic consumption. These data were reviewed monthly, quarterly, and yearly along with antibiotic susceptibility patterns on a semi-annual basis. Segmented regression analysis was use to compare restricted antibiotic purchases for performance periods of 1998–2001 (construction), 2002–2004 (de-construction), and 2005–2011 (reconstruction). After 4 years (1998–2001) of operation, a number of key participants of the ASP departed. For the following three years (2002–2004) the intensity and focus of the program floundered. This trend was averted when the program was revitalized in early 2005. The construction, deconstruction, and reconstruction of our ASP provided a unique opportunity to statistically examine the financial impact of our ASP or lack thereof in the same institution. We demonstrate a significant economic impact during ASP deconstruction and reconstruction.
References
[1]
Fishman, N.; Patterson, J.; Saiman, L.; Srinivasan, A.; Trivedi, K.K.; van Schooneveld, T.; Lynfield, R.; Gerding, D.; Septimus, E.; Schwartz, D.; et al. Policy statement on antimicrobial stewardship by the society for healthcare epidemiology, the infectious diseases society of America, and the pediatric infectious diseases society. Infect. Control Hosp. Epidemiol. 2012, 33, 322–327, doi:10.1086/665010.
[2]
Dellit, T.H.; Owens, R.C.; McGowan, J.E.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskings, W.C.; Paterson, D.L.; Fishman, N.O; Carpenter, C.F.; et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 2007, 44, 159–177.
Beardsley, J.R.; Willamson, J.C.; Johnson, J.W.; Luther, V.P.; Wrenn, R.H.; Ohl, C.C. Show me the money: Long-term financial impact of an antimicrobial stewardship program. Infect. Control Hosp. Epidemiol. 2012, 33, 398–400, doi:10.1086/664922.
[5]
Nowak, M.A.; Nelson, R.E.; Briedenbach, J.L.; Thompson, P.A.; Carson, P.J. Clinical and economic outcomes of a prospective antimicrobial stewardship program. Am. J. Health Syst. Pharm. 2012, 69, 1500–1508, doi:10.2146/ajhp110603.
[6]
Bosso, J.A.; Maudlin, P.D. Assessment of effects of fluoroquinolone formulary changes on Gram-negative susceptibility and MRSA isolation rates using interrupted time series analysis. Antimicrob. Agents Chemother. 2006, 50, 2106–2112, doi:10.1128/AAC.01359-05.